Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation: 2023-2025

Historic Share-based Compensation for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $7.3 million.

  • CG Oncology's Share-based Compensation rose 176.75% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 240.46%. This contributed to the annual value of $11.4 million for FY2024, which is 646.20% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Share-based Compensation is $7.3 million, which was up 4.62% from $7.0 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Share-based Compensation registered a high of $7.3 million during Q3 2025, and its lowest value of $177,000 during Q2 2023.
  • Its 3-year average for Share-based Compensation is $2.9 million, with a median of $2.2 million in 2024.
  • Data for CG Oncology's Share-based Compensation shows a peak YoY spiked of 1,168.93% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Share-based Compensation stood at $778,000 in 2023, then skyrocketed by 541.39% to $5.0 million in 2024, then spiked by 176.75% to $7.3 million in 2025.
  • Its last three reported values are $7.3 million in Q3 2025, $7.0 million for Q2 2025, and $5.2 million during Q1 2025.